Starpharma Holdings Ltd has released a press release.
Enrolment complete for Phase 3 VivaGel BV-R program
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- VivaGel condom receives regulatory approval in Canada
- New DEP drug delivery program initiated with AstraZeneca
- Starpharma signs license for a VivaGel condom in China
- Appendix 4C - Quarterly Cashflow Reoprt
- Starpharmas DEP eliminates cabazitaxel neutropenia
Later from Starpharma
- Additional Priostar Glyphosate Patent Allowed in US
- Starpharma signs license for VivaGel Condom in Iran
- Starpharma receives $3.5M R&D tax incentive refund
- VivaGel BV granted QIDP and Fast Track designation by US FDA
- Shareholder Update January 2017
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma